Duanfeng F. Jiang
Haikou, 570311, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Bone marrow plasma cytokine composition indicates acute myeloid leukemia progression and treatment response.
Journal: Frontiers in cell and developmental biology
Published: March 31, 2026
Retraction Note: Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.
Journal: Journal of nanobiotechnology
Published: January 17, 2025
The clinical significance of TAT, PIC, TM, and t-PAIC in vascular events of BCR/ABL-negative myeloproliferative neoplasms.
Journal: Clinical and experimental medicine
Published: April 10, 2024
Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
Journal: Cancer medicine
Published: February 28, 2024
Exosome-shuttled FTO from BM-MSCs contributes to cancer malignancy and chemoresistance in acute myeloid leukemia by inducing m6A-demethylation: A nano-based investigation.
Journal: Environmental research
Published: May 31, 2023
m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemia.
Journal: BMC medical genomics
Published: April 13, 2023
Targeting gut microbial nitrogen recycling and cellular uptake of ammonium to improve bortezomib resistance in multiple myeloma.
Journal: Cell metabolism
Published: April 10, 2023
MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells.
Journal: Stem cells international
Published: August 12, 2022
Clinical implications and genetical insights of SOX6 expression in acute myeloid leukemia.
Journal: Journal of cancer research and clinical oncology
Published: July 04, 2022
Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab.
Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab.
Journal: Journal of oncology
Published: June 29, 2022
Hypoxia-Immune-Related Gene SLC19A1 Serves as a Potential Biomarker for Prognosis in Multiple Myeloma.
Journal: Frontiers in immunology
Published: December 25, 2021
Last Updated: 09/26/2026